Absci Corporation has begun dosing patients in the first human trial of ABS-201, a monoclonal antibody designed entirely by generative AI. The Phase 1/2a trial, dubbed HEADLINE, kicked off on December 4, 2025, in Australia, marking what may be one of the fastest concept-to-clinic timelines in biotech history: approximately 24 months.
What ABS-201 actually does
The drug targets the prolactin receptor, or PRLR, with the goal of enhancing hair follicle regeneration. In plain terms, it’s a treatment for androgenetic alopecia, the most common form of hair loss.
ABS-201 has been engineered with an extended half-life, meaning it stays active in the body longer than standard antibodies. Preclinical data showed it produced superior hair regrowth compared to existing options. The HEADLINE trial is randomized, double-blind, and placebo-controlled, involving up to 227 healthy participants, both with and without hair loss conditions.
A multi-ascending dose portion of the trial is expected in Q2 2026. Proof-of-concept data should arrive in the second half of 2026.
